Medline (NASDAQ:MDLN) Insider Douglas Golwas Sells 100,000 Shares

Medline (NASDAQ:MDLN – Get Free Report) insider Douglas Golwas sold 100,000 shares of the business’s stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $36.77, for a total value of $3,677,000.00. Following the completion of the sale, the insider owned 23,899 shares of the company’s stock, valued at $878,766.23. This trade represents a 80.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Medline Price Performance

MDLN opened at $36.42 on Thursday. The firm has a fifty day moving average price of $40.33. The company has a market cap of $47.84 billion and a P/E ratio of 113.81. Medline has a 1 year low of $32.81 and a 1 year high of $50.88. The company has a debt-to-equity ratio of 0.65, a current ratio of 4.41 and a quick ratio of 2.51.

Get Medline alerts:

Medline (NASDAQ:MDLN – Get Free Report) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.33 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.29 by $0.04. The firm had revenue of $7.35 billion during the quarter. The firm’s quarterly revenue was up 10.7% compared to the same quarter last year. Equities analysts anticipate that Medline will post 1.49 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. BTIG Research restated a “buy” rating and set a $55.00 price objective on shares of Medline in a research report on Thursday, May 7th. Barclays dropped their target price on Medline from $50.00 to $45.00 and set an “overweight” rating for the company in a research report on Monday, June 1st. Stifel Nicolaus set a $55.00 price target on Medline in a research note on Wednesday, February 25th. JPMorgan Chase & Co. increased their price target on Medline from $50.00 to $53.00 and gave the company an “overweight” rating in a research note on Tuesday, March 10th. Finally, BNP Paribas Exane decreased their target price on Medline from $49.00 to $40.00 and set a “neutral” rating for the company in a research note on Thursday, May 14th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $50.54.

Get Our Latest Stock Analysis on MDLN

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Sound Income Strategies LLC purchased a new position in shares of Medline during the fourth quarter valued at approximately $25,000. Entrust Financial LLC purchased a new position in Medline in the fourth quarter worth $26,000. NBC Securities Inc. purchased a new position in Medline in the fourth quarter worth $28,000. Whipplewood Advisors LLC bought a new stake in shares of Medline in the first quarter valued at $30,000. Finally, Global Retirement Partners LLC bought a new stake in shares of Medline in the fourth quarter valued at $31,000.

About Medline

(Get Free Report)

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.

Featured Stories

• Five stocks we like better than Medline
• Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
• CoreWeave Insider Sales Look Big, But Should Investors Worry?
• Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
• Meta and Cloud Computing: Real Potential, or a Shot in the Dark?

Receive News & Ratings for Medline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medline and related companies with MarketBeat.com's FREE daily email newsletter.